Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
MEGACE |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Progestin. |
| Generic Name |
|
Megestrol acetate 20mg, 40mg; scored tabs. |
| Indications |
|
Palliative treatment of advanced breast or endometrial carcinoma. |
| Children |
|
Not applicable. |
| Adults |
|
Breast carcinoma: 40mg 4 times daily. Endometrial carcinoma: 40–320mg daily in divided doses. |
| Precautions |
|
History of thromboembolic disease. Diabetes. Monitor for adrenal insufficiency. Pregnancy (Cat.D), nursing mothers: not recommended. |
| Interactions |
|
May increase insulin requirements. Decreases indinavir levels. |
| Adverse Reactions |
|
Weight gain, thromboembolic events, heart failure, GI upset, edema, breakthrough menstrual bleeding, dyspnea, tumor flare, hyperglycemia, alopecia, hypertension, carpal tunnel syndrome, mood changes, hot flashes, malaise, asthenia, lethargy, sweating, rash. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
